cbdMD Q4 net sales expected to rise 3-5% YoY, FY22 revenue $19.1-$19.3mln.

• cbdMD reports preliminary Q4 and FY25 results • Net sales revenue expected to remain in line with prior year • Q4 net sales expected to increase 3-5% YoY • FY25 net sales expected to range between $19.1-19.3mln • FY25 net sales expected to be in line with prior year • Company's domestic production and Farm Bill-compliant Delta-9 offerings drive growth • cbdMD is a leading CBD brand in the US with a comprehensive product line